Method and system for addressing adverse effects on the oral microbiome and restoring gingival health caused by sodium lauryl sulphate exposure
Sheri Simmons, Brookline, MA (US); Tye Jensen, Telluride, CO (US); and Joseph E. Kovarik, Englewood, CO (US)
Assigned to Seed Health, Inc., Venice, CA (US)
Filed by SEED HEALTH, INC., Venice, CA (US)
Filed on Aug. 16, 2023, as Appl. No. 18/234,544.
Application 18/234,544 is a continuation in part of application No. 18/103,768, filed on Jan. 31, 2023, granted, now 11,844,720.
Application 18/103,768 is a continuation in part of application No. 17/738,771, filed on May 6, 2022.
Application 17/738,771 is a continuation in part of application No. 16/904,056, filed on Jun. 17, 2020, granted, now 11,523,934, issued on Dec. 13, 2022.
Application 16/904,056 is a continuation in part of application No. 15/983,250, filed on May 18, 2018, granted, now 10,687,975, issued on Jun. 23, 2020.
Application 15/983,250 is a continuation in part of application No. 15/384,716, filed on Dec. 20, 2016, granted, now 9,987,224, issued on Jun. 5, 2018.
Application 18/234,544 is a continuation in part of application No. 15/270,034, filed on Sep. 20, 2016, granted, now 9,750,802, issued on Sep. 5, 2017.
Application 15/270,034 is a continuation in part of application No. 15/228,454, filed on Aug. 4, 2016, granted, now 9,585,920, issued on Mar. 7, 2017.
Application 15/270,034 is a continuation of application No. 14/954,074, filed on Nov. 30, 2015, granted, now 9,457,077, issued on Oct. 4, 2016.
Application 18/234,544 is a continuation in part of application No. 14/752,192, filed on Jun. 26, 2015, granted, now 9,549,842, issued on Jan. 24, 2017.
Application 14/752,192 is a continuation in part of application No. 14/611,458, filed on Feb. 2, 2015, granted, now 10,398,209, issued on Sep. 3, 2019.
Application 14/954,074 is a continuation in part of application No. 14/574,517, filed on Dec. 18, 2014, granted, now 9,408,880, issued on Aug. 9, 2016.
Application 14/611,458 is a continuation of application No. 14/502,097, filed on Sep. 30, 2014, granted, now 9,010,340, issued on Apr. 21, 2015.
Application 14/502,097 is a continuation of application No. 14/307,651, filed on Jun. 18, 2014, granted, now 8,936,030, issued on Jan. 20, 2015.
Application 14/752,192 is a continuation in part of application No. 14/225,503, filed on Mar. 26, 2014, granted, now 9,445,936, issued on Sep. 20, 2016.
Application 14/307,651 is a continuation in part of application No. 14/079,054, filed on Nov. 13, 2013, granted, now 8,757,173, issued on Jun. 24, 2014.
Application 14/079,054 is a continuation of application No. 13/425,913, filed on Mar. 21, 2012, granted, now 8,584,685, issued on Nov. 19, 2013.
Application 14/225,503 is a continuation of application No. 13/367,052, filed on Feb. 6, 2012, granted, now 8,701,671, issued on Apr. 22, 2014.
Claims priority of provisional application 62/275,341, filed on Jan. 6, 2016.
Claims priority of provisional application 62/274,550, filed on Jan. 4, 2016.
Claims priority of provisional application 62/387,404, filed on Dec. 24, 2015.
Claims priority of provisional application 62/387,405, filed on Dec. 24, 2015.
Claims priority of provisional application 62/072,476, filed on Oct. 30, 2014.
Claims priority of provisional application 62/053,926, filed on Sep. 23, 2014.
Claims priority of provisional application 62/014,855, filed on Jun. 20, 2014.
Claims priority of provisional application 61/919,297, filed on Dec. 20, 2013.
Claims priority of provisional application 61/556,023, filed on Nov. 4, 2011.
Claims priority of provisional application 61/467,767, filed on Mar. 25, 2011.
Claims priority of provisional application 61/439,652, filed on Feb. 4, 2011.
Prior Publication US 2024/0024154 A1, Jan. 25, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. A61F 5/56 (2006.01)
CPC A61F 5/566 (2013.01)
20 Claims
1. A method for reducing the likelihood of developing dental caries and halitosis, comprising:
providing to an oral cavity of an individual subject:
a first bacterial composition comprising beneficial bacteria adapted to form a biofilm, said beneficial bacteria comprising a bacterium of the genus Rothia;
a second composition comprising:
an oral probiotic comprising at least two of the following bacteria: Lactobacillus brevis CD2, Streptococcus sanguinis BCC23, Lactobacillus acidophilus, Lactobacillus bulgaricus, Lactobacillus johnsonii, Bifidobacterium bifidum, Enterococcus faecium, Lactobacillus rhamnosus, Lactobacillus plantarum, Lactobacillus reuteri, Lactobacillus paracasei, Lactobacillus casei, Lachnospira, Veillonella, Faecalibacterium and Prevotella;
at least one zinc-based compound selected from the group consisting of zinc acetate, zinc chloride, zinc citrate, and zinc sulphate; and
at least one bioactive flavonoid selected from the group consisting of baicalein, naringenin, catechins, quercetin, trans-resveratrol, luteolin, kaempferol, hesperidin, hesperetin, naringin, diosmin, rutin, nobiletin, and tangeretin; and
wherein the oral probiotic lowers the pH of the individual subject's oral cavity in an amount sufficient to disrupt the formation of biofilms by pathogenic bacteria.